Who is the manufacturer of ADAS 3D?

Adas3D Medical S.L. filed the 510(k) submission for ADAS 3D (K210850).

What is the FDA product code for ADAS 3D?

LLZ. It is classified under 21 CFR 892.2050 as a Class 2 device in the Radiology panel.

What is the regulatory pathway for ADAS 3D?

510(k) clearance (submission type: Special).

Who can help prepare an FDA 510(k) submission like ADAS 3D?

Innolitics — a medical-device software consultancy — provides regulatory and engineering support for FDA 510(k) submissions. See https://innolitics.com/services/510ks/ or contact https://innolitics.com/contact.

ADAS 3D

K210850 · Adas3D Medical S.L. · LLZ · Apr 5, 2021 · Radiology

Device Facts

Record ID	K210850
Device Name	ADAS 3D
Applicant	Adas3D Medical S.L.
Product Code	LLZ · Radiology
Decision Date	Apr 5, 2021
Decision	SESE
Submission Type	Special
Regulation	21 CFR 892.2050
Device Class	Class 2
Attributes	Software as a Medical Device

Intended Use

ADAS 3D is indicated for use in clinical settings to support the visualization and analysis of MR and CT images of the heart for use on individual patients with cardiovascular disease. ADAS 3D is indicated for patients with myocardial scar produced by ischemic or non-ischemic heart disease. ADAS 3D processes MR and CT images. The quality and the resolution of the medical images determines the accuracy of the data produced by ADAS 3D. ADAS 3D is indicated to be used only by qualified medical professionals (cardiologists, electrophysiologists, radiologists or trained technicians) for the calculation, quantification and visualization of cardiac images and intended to be used for pre-planning and during electrophysiology procedures. The data produced by ADAS 3D must not be used as an irrefutable basis or a source of medical advice for clinical diagnosis or patient treatment. The data produced by ADAS 3D is intended to be used to support qualified medical professionals for clinical decision making. The clinical significance of using ADAS 3D to identify arrhythmia substrates for the treatment of cardiac arrhythmias (e.g., ventricular tachycardia) or risk stratification has not been established.

Device Story

ADAS 3D is a standalone software application for post-processing cardiovascular MRI and CTA DICOM images. It enables calculation, quantification, and 3D visualization of myocardial enhancement (fibrosis) and cardiac anatomy. The software identifies and quantifies Left Ventricle (LV) wall thickness, LV/Left Atrium (LA) enhancement, and 3D corridors of intermediate signal intensity. Used in clinical settings by cardiologists, electrophysiologists, radiologists, or technicians, the device exports data to industry-standard formats for viewing on external systems, including EP navigation systems. It supports clinical decision-making by providing 3D models and numerical data; however, it is not intended to identify regions for catheter ablation or treatment of arrhythmias, and its clinical significance for arrhythmia substrate identification or risk stratification is not established.

Clinical Evidence

No clinical data. The device is a software-based image processing tool; substantial equivalence is based on identical technological characteristics and intended use to the predicate device.

Technological Characteristics

Standalone software for Windows 10 (64-bit). Requires minimum 8GB RAM, 100GB disk space, and DirectX 10 capable graphics. Processes DICOM MR/CT images. Features include 3D multiplanar reconstruction, enhancement quantification, and 3D corridor detection. Exports data as PNG, MPEG, TXT, or VTK/DIF meshes.

Indications for Use

Indicated for patients with myocardial scar from ischemic or non-ischemic heart disease. Used by cardiologists, electrophysiologists, radiologists, or trained technicians for cardiac image visualization, quantification, and pre-planning/during electrophysiology procedures.

Regulatory Classification

Identification

A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.

Special Controls

*Classification.* Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).

Predicate Devices

ADAS 3D (K191125)

Related Devices

K212421 — ADAS 3D · Adas3D Medical S.L. · Sep 3, 2021
K230803 — ADAS 3D · Adas3D Medical S.L. · May 23, 2023
K191125 — ADAS 3D · Galgo Medical S.L · Jan 15, 2020
K240791 — ADAS 3D · Adas3D Medical S.L. · Sep 9, 2024
K131158 — CORVIEW · Marrek, Inc. · Aug 21, 2013

Submission Summary (Full Text)

{0}------------------------------------------------ April 5, 2021 Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue. Adas3D Medical S.L. % Antonio Riu General Manager Paris 179, 2-2 Barcelona, Barcelona 08036 SPAIN Re: K210850 Trade/Device Name: ADAS 3D Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: Class II Product Code: LLZ Dated: March 17, 2021 Received: March 22, 2021 Dear Antonio Riu: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for {1}------------------------------------------------ devices or postmarketing safety reporting (21 CFR 4. Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Michael D. O'Hara For Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K210850 Device Name ADAS 3D #### Indications for Use (Describe) ADAS 3D is indicated for use in clinical settings to support the visualization and analysis of MR and CT images of the heart for use on individual patients with cardiovascular disease. ADAS 3D is indicated for patients with myocardial scar produced by ischemic heart disease. ADAS 3D processes MR and CT images. The quality and the resolution of the medical images determines the accuracy of the data produced by ADAS 3D. ADAS 3D is indicated to be used only by qualified medical professionals ( cardiologists, radiologists, radiologists, radiologists, or trained technicians) for the calculation and visualization of cardiac images and intended to be used for pre-planning and during electrophysiology procedures. The data produced by ADAS 3D must not be used as an irrefutable basis or a source of medical advice for clinical diagnosis or patient treatment. The data produced by ADAS 3D is intended to be used to support qualified medical professionals for clinical decision making. The clinical significance of using ADAS 3D to identify arrhythmia substrates for the treatment of cardiac arrhythmias ( e.g., ventricular tachycardia) or risk stratification has not been established. | Type of Use (Select one or both, as applicable) | | |---------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------| | <div> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> Over-The-Counter Use (21 CFR 801 Subpart C) </div> | ### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ # 510(K) SUMMARY | SUBMITTER NAME: | ADAS3D MEDICAL S.L | |--------------------|--------------------------------------------------------------| | SUBMITTER ADDRESS: | C/ Paris 179, 2°-2° 08036 Barcelona BARCELONA SPAIN | | CONTACT: | Antoni Riu | | TELEPHONE: | +34 93 328 3964 | | e-mail: | Antoni.riu@adas3d.com | | DEVICE TRADE NAME: | ADAS 3D | | COMMON NAME: | Radiological Image Processing System | CLASSIFICATION NAME: Radiological Image Processing System (21 CFR 892.2050) PRODUCT CODE: LLZ REGULATION DESCRIPTION: Picture archiving and communications system O PREDICATE DEVICE(S): ADAS 3D (K191125) ### 1. DEVICE DESCRIPTION ADAS 3D is a software-based image processing tool for post-processing cardiovascular enhanced Magnetic Resonance (MRI) images and Computed Tomography Angiography (CTA) images. ADAS 3D is designed to process DICOM image databases to enable the calculation, quantification and visualization of 3D cardiac imaging data by displaying and quantifying the levels of enhancement. ADAS 3D also enables the visualization of the shape of the cardiac chamber and the adjacent anatomy. After data processing, the data and images can be exported utilizing industry standard for viewing on other systems, including Electrophysiology (EP) navigation systems. The following table lists the principal characteristics and features of the software: | Characteristics / Feature | ADAS 3D | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | General Features | | | Operation System | Min. 64-bit Microsoft Windows 10 Rec. 64-bit Microsoft® Windows® 10 | | CPU Type | Min. Intel® Pentium® 4 or AMD Athlon™ 64, 3 GHz or faster or Intel® or AMD dual core 2 GHz or faster Rec. Intel® Core i74790 K or equivalent | | Memory | Min. 8 GB RAM Rec. 16 GB RAM | | Disk Space | Min. 100 GB free disk space for local study database Rec. 250 GB free disk space or more for local study database | | Graphics | Min. Microsoft® DirectX 10® capable graphics card or higher Rec. Microsoft® DirectX 11® or capable graphics card or higher (for example GeForce GT 730) | | Other | 1,280 x 1,024 or higher screen resolution | | Input file formats | DICOM/DICOMDIR | | System Interface | -DICOM: Digital Imaging and Communications in Medicine (DICOM) is a standard for handling, storing, printing, and transmitting information in medical imaging. -LIEBRE Study: A LIEBRE study is a set of files storing each processed case. - Navigation System File Format: Format for Navigation system. Snapshots: Snapshots in PNG format. -Videos: Videos in MPEG format and MPEG-1 video codec. | | User Interface | -Application workflow navigation tool. -Toolbar. - Working area. -Toolbox. | | Functional Features | | | Functions | -Importing Cardiac Imaging (MRI/CTA) in DICOM format MRI Images support: • Visualization of the distribution of the enhancement in a three-dimensional (3D) chamber of the heart • Quantification of the total volume of the enhancement within the Left Ventricle (LV) and the visualization of the enhancement area in multiple layers through the cardiac structure • Calculation, quantification and visualization of corridors of intermediate signal intensity enhancement in the LV • Quantification and visualization of the total area and distribution of the enhancement within the Left Atrium (LA) CTA images support: • Quantification of LV wall thickness • Identification and Visualization of other 3D anatomical structures - The ADAS 3D exports data into industry standard file formats supported by catheter navigation systems | | Data Storage | All analysis results can be saved and reloaded again for reviewing and/or exporting. The analysis results include the input DICOM image, 3D models, numerical values, snapshots and videos. | | Software Algorithms | -Left Ventricle Layer Computation -Left Atrium Layer Computation Algorithm -Enhancement Quantification Algorithm -3D Corridor Detection Algorithm -Heart Anatomy Extraction Algorithm -From Binary image to surface mesh Algorithm -Left Ventricle Wall Thickness Algorithm | {4}------------------------------------------------ {5}------------------------------------------------ ## 2. 3D CORRIDORS MODULE The 3D Corridors Module is an automatic detection feature designed to help identify and visualize 3D corridors of border zone (BZ) tissue within the LV. The 3D Corridors algorithm generates visual representations of the corridors that may travel through multiple layers of the LV. A 3D Corridor is defined as a path of BZ tissue (or an area of intermediate intensity on the MRI) that starts and ends in healthy tissue (HT) and travels between areas of core scar (CS) tissue. A corridor is a three-dimensional path in the myocardium and has an associated volume. The ADAS 3D software distinguishes between protected and unprotected regions for a corridor. - A protected region of BZ tissue is defined as the corridor that is embedded in an area . of CS. - An unprotected region of BZ tissue is defined as BZ tissue that is not surrounded by . CS. The ADAS 3D software only calculates 3D Corridors using the layers in between the endo and epicardium. The mitral value and the endo and epicardial surfaces define the boundaries for 3D Corridor detection, they are considered as CS tissue by the software. To be automatically identified, by ADAS 3D, as a 3D Corridor, four criteria must be met in at least one layer: - 1. It must pass through a BZ region - 2. It must connect two HT regions - 3. It must be protected by the CS region both - a. Within its layer, on both sides and by a minimum CS size - b. AND surrounding the layer - 4. It must have a minimum length of 5 mm {6}------------------------------------------------ ## 3. SUMMARY OF COMPARISON WITH PREDICATE DEVICE The ADAS 3D device that is the subject of this Special 510(k) is identical to the ADAS 3D device cleared under (K191125). Only clarifications to the Indications for Use and Precautions sections have been made as noted with use of bold (added language) and strikethrough (deleted language) fonts in the following table. These labelling changes do not impact the safety or effectiveness of the device. | Elements of Comparison | Predicate Device ADAS 3D (ADAS3D MEDICAL S.L) K191125 | Modified Device ADAS 3D (ADAS3D MEDICAL S.L) | |----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Regulatory Data | | | | Regulatory Class | Class II | Class II | | Classification name | Radiological Image processing system | Radiological Image processing system | | Regulation Number | 21 CFR 892.2050 | 21 CFR 892.2050 | | Product Code | LLZ | LLZ | | 510(k) Number | K191125 | To be assigned | | Use | | | | Indication for Use | ADAS 3D is indicated for use in clinical settings to support the visualization and analysis of MR and CT images of the heart for use on individual patients with cardiovascular disease. ADAS 3D is indicated for patients with myocardial scar produced by ischemic or non-ischemic heart disease. ADAS 3D processes MR and CT images. The quality and the resolution of the medical images determines the accuracy of the data produced by ADAS 3D. ADAS 3D is indicated to be used only by qualified medical professionals for the visualization and analysis of cardiac images. The data produced by ADAS 3D must not be used as an irrefutable basis or a source of medical advice for clinical diagnosis or patient treatment. The data produced by ADAS 3D is intended to be used to support qualified medical professionals for clinical decision making | ADAS 3D is indicated for use in clinical settings to support the visualization and analysis of MR and CT images of the heart for use on individual patients with cardiovascular disease. ADAS 3D is indicated for patients with myocardial scar produced by ischemic or non-ischemic heart disease. ADAS 3D processes MR and CT images. The quality and the resolution of the medical images determines the accuracy of the data produced by ADAS 3D. ADAS 3D is indicated to be used only by qualified medical professionals (cardiologists, electrophysiologists, radiologists or trained technicians) for the calculation, quantification and visualization of cardiac images and intended to be used for pre-planning and during electrophysiology procedures. The data produced by ADAS 3D must not be used as an irrefutable basis or a source of medical | | Elements of Comparison | Predicate Device ADAS 3D (ADAS3D MEDICAL S.L) K191125 | Modified Device ADAS 3D (ADAS3D MEDICAL S.L) | | | ADAS 3D is not intended to identify regions for catheter ablation or treatment of arrhythmias. | advice for clinical diagnosis or patient treatment. The data produced by ADAS 3D is intended to be used to support qualified medical professionals for clinical decision making. ADAS 3D is not intended to identify regions for catheter ablation or treatment of arrhythmias. The clinical significance of using ADAS 3D to identify arrhythmia substrates for the treatment of cardiac arrhythmias (e.g., ventricular tachycardia) or risk stratification has not been established. | | Precautions | The software is not intended to identify regions for catheter ablation or treatment of arrhythmias. This software is a tool to support clinicians for better visualization of cardiac images from MR and CTA. It is up to the clinicians to make their own interpretations of the information that is presented. The intermediate signal intensity “3D Corridor” detection tool is not intended for clinical patient management and its use has not been validated clinically. The results are explicitly not to be regarded as the sole, irrefutable basis for clinical diagnosis. | The software is not intended to identify regions for catheter ablation or treatment of arrhythmias. This software is a tool to support clinicians for better visualization of cardiac images from MR and CTA. It is up to the clinicians to make their own interpretations of the information that is presented. The intermediate signal intensity “3D Corridor” detection tool is not intended for clinical patient management and its use has not been validated clinically. The results are explicitly not to be regarded as the sole, irrefutable basis for clinical diagnosis. The software has not been validated for identifying arrhythmia substrates and should not be used as the sole source of information for treatment planning. The clinical significance of using the | | Elements of Comparison | Predicate Device ADAS 3D (ADAS3D MEDICAL S.L) K191125 | Modified Device ADAS 3D (ADAS3D MEDICAL S.L) | | Intended use | ADAS 3D is intended to be used for post- processing cardiovascular enhanced Magnetic Resonance (MR) images and Computed Tomography Angiography (CTA) images that are formatted in Digital Imaging and Communication in Medicine (DICOM) standard. ADAS 3D is intended for the non- invasive calculation, quantification and visualization of cardiac imaging data to support a comprehensive diagnostic decision- making process for understanding cardiovascular disease. ADAS 3D analyzes the enhancement of myocardial fibrosis from DICOM MR images to support: • Visualization of the distribution of the enhancement in a three-dimensional (3D) chamber of the heart. • Quantification of the total volume of the enhancement within the left Ventricle (LV) and the visualization of the enhancement area in multiple layers through the cardiac structure. • Calculation, quantification and visualization of corridors of intermediate signal intensity enhancement in the LV. • Quantification and visualization of the total area and distribution of the enhancement within the Left Atrium (LA). Additionally, ADAS 3D imports DICOM CTA images to support: • Quantification of the wall thickness of the LV. • Identification and visualization of other 3D anatomical structures. ADAS-3D exports information to multiple industry standard file formats suitable for documentation and information sharing purposes. The 3D data is exported into | No change | | | | tachycardia) or risk stratification has not been established. | | Elements of Comparison | Predicate Device ADAS 3D (ADAS3D MEDICAL S.L) K191125 | Modified Device ADAS 3D (ADAS3D MEDICAL S.L) | | | industry standard file formats supported by catheter navigation systems. It is intended to be used by qualified medical professionals (cardiologists, electrophysiologists, radiologists or trained technicians) experienced in examining and evaluating cardiovascular MR and CTA images as part of the comprehensive diagnostic decision- making process. ADAS-3D is a standalone software application. The target population of the use of ADAS-3D is not restricted | | | Technical characteristics | | | | General description | Is a software solution for the visualization and analysis of cardiovascular MR and CT images. | No change | | Mode of action | Software Solution | No change | | Operating System | Windows…